Visualitzant CEMCAT - Articles científics per títol
Ara mostrant els elements 36-55 d 106
-
Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis
(Lippincott Williams & Wilkins, 2022-07) -
Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial
(Wolters Kluwer Health, 2024-03-12) -
Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS
(Elsevier, 2021-02) -
Expert-Agreed Practical Recommendations on the Use of Cladribine
(Springer, 2022-12) -
Genetic influences on disease course and severity, 30 years after a clinically isolated syndrome
(Oxford University Press, 2023) -
Genetic variation in NDFIP1 modifies the metabolic patterns in immune cells of multiple sclerosis patients
(Nature Research, 2021-11-01) -
Immunomodulatory Effects Associated with Cladribine Treatment
(MDPI, 2021-12) -
Immunosenescence in multiple sclerosis: the identification of new therapeutic targets
(Elsevier, 2021-09) -
Increased NLRP3 Inflammasome Activation and Pyroptosis in Patients With Multiple Sclerosis With Fingolimod Treatment Failure
(Wolters Kluwer Health, 2023-05) -
Inteligencia artificial en esclerosis múltiple
(Permanyer, 2023) -
Liquid Biopsy in Neurological Diseases
(MDPI, 2023-07-22)